Mostrar el registro sencillo del ítem

dc.contributor.authorGonzalez-Calero, Laura
dc.contributor.authorMartinez, Paula J.
dc.contributor.authorMartin-Lorenzo, Marta
dc.contributor.authorBaldan-Martin, Montserrat
dc.contributor.authorRuiz-Hurtado, Gema
dc.contributor.authorde la Cuesta, Fernando
dc.contributor.authorCalvo, Eva
dc.contributor.authorSegura, Julian
dc.contributor.authorLopez, Juan Antonio 
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorBarderas, Maria G
dc.contributor.authorRuilope, Luis M
dc.contributor.authorVivanco, Fernando
dc.contributor.authorAlvarez-Llamas, Gloria
dc.date.accessioned2017-10-20T10:23:10Z
dc.date.available2017-10-20T10:23:10Z
dc.date.issued2017
dc.identifierISI:000405498000052
dc.identifier.citationOncotarget. 2017; 8(27):44217-44231
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/20.500.12105/5107
dc.description.abstractAlbuminuria is an indicator of cardiovascular risk and renal damage in hypertensive individuals. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure control and prevents development of new-onset-albuminuria. A significant number of patients, however, develop albuminuria despite chronic RAS blockade, and the physiopathological mechanisms are underexplored. Urinary exosomes reflect pathological changes taking place in the kidney. The objective of this work was to examine exosomal protein alterations in hypertensive patients with albuminuria in the presence of chronic RAS suppression, to find novel clues underlying its development. Patients were followed-up for three years and were classified as: a) patients with persistent normoalbuminuria; b) patients developing de novo albuminuria; and c) patients with maintained albuminuria. Exosomal protein alterations between groups were identified by isobaric tag quantitation (iTRAQ). Confirmation was approached by target analysis (SRM). In total, 487 proteins were identified with high confidence. Specifically, 48 proteins showed an altered pattern in response to hypertension and/or albuminuria. Out of them, 21 proteins interact together in three main functional clusters: glycosaminoglycan degradation, coagulation and complement system, and oxidative stress. The identified proteins constitute potential targets for drug development and may help to define therapeutic strategies to evade albuminuria progression in hypertensive patients chronically treated.
dc.description.sponsorshipInstituto de Salud Carlos III, fondos FEDER/FSE (PI11/01401, PI13/01873, PI14/01841, IF08/3667-1, PI11-02239, PI 14/0917, PI11/02432, PI13/01746, PI14/01650, PI16/01334, PT13/0001/0013, CP09/00229, CP15/00129, CPII15/00027), Fundacion SENEFRO, Fundacion Conchita Rabago de Jimenez Diaz, and Redes Tematicas de Investigacion Cooperativa (fondos FEDER/FSE, RD12/0021/0001, RD12/0042/0071). These results are lined up with the Spanish initiative on the Human Proteome Project (SpHPP).
dc.language.isoeng
dc.publisherImpact Journals 
dc.type.hasVersionVoR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectExosomes
dc.subjectHypertension
dc.subjectAlbuminuria
dc.subjectRenin-angiotensin system
dc.subjectProteomics
dc.subjectCHRONIC KIDNEY-DISEASE
dc.subjectDIABETIC-NEPHROPATHY
dc.subjectHEPARAN-SULFATE
dc.subjectCOMPLEMENT C3
dc.subjectEXTRACELLULAR VESICLES
dc.subjectPEPTIDE IDENTIFICATION
dc.subjectSYSTEM SUPPRESSION
dc.subjectPROTEOMIC ANALYSIS
dc.subjectEPITHELIAL-CELLS
dc.subjectPROGNOSTIC VALUE
dc.titleUrinary exosomes reveal protein signatures in hypertensive patients with albuminuria
dc.typejournal article
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID28562335
dc.format.volume8
dc.format.page44217-44231
dc.identifier.doi10.18632/oncotarget.17787
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderFundación SENEFRO 
dc.contributor.funderFundación Conchita Rábago de Jiménez Díaz 
dc.contributor.funderRedes Temáticas de Investigación Cooperativa en Salud (RETICS) (España) 
dc.description.peerreviewed
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.17787
dc.identifier.journalOncotarget
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovascular
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómica
dc.repisalud.institucionCNIC
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/01401es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/01873es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01841es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/IF08/3667-1es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/02239es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/0917es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/02432es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/01746es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01650es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01334es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PT13/0001/0013es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CP09/00229es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CP15/00129es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CPII15/00027es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0021/0001es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0042/0071es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional